Better cancer specific survival in young small cell lung cancer patients especially with AJCC stage III

Abstract

// Haiyong Wang 1 , Jingze Zhang 1 , Fang Shi 1 , Chenyue Zhang 2 , Qinghua Jiao 3 , Hui Zhu 1 1 Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan 250117, China 2 Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China 3 Cancer Center, The Second Hospital of Shandong University, Shandong 250033, China Correspondence to: Haiyong Wang, email: wanghaiyong6688@126.com Hui Zhu, email: drzhuhui@163.com Keywords: small cell lung cancer, young, cancer specific survival, SEER Received: September 16, 2016      Accepted: March 24, 2017      Published: April 04, 2017 ABSTRACT It has been reported that younger patients with non-small cell lung cancer (NSCLC) tend to have a better prognosis. Yet, few studies have focused on the clinicopathological characteristics and prognosis of young small cell lung cancer (SCLC), especially for patients with age < 50. In our study, we used Surveillance, Epidemiology, and End Results (SEER) population-based data and identified 16503 patients with SCLC including 711 patients aged < 50, 3338 patients aged 50–59, 5937 patients aged 60–69, 4649 patients aged 70–79 and 1868 patients aged ≥ 80 between 2010 and 2013. The Kaplan-Meier methods was used to develop the survival curve, and the results showed that the SCLC patients with aged < 50 tended to a better over survival (OS) and cancer specific survival (CSS) (all, P < 0.001). In addition, Cox regression model was used to analyze survival prognosis factors and perform subgroup analysis. The results showed that age was an independent prognostic factor for CSS ( P < 0.001). Importantly, we found that for the patients with AJCC stage III subgroup, the age < 50 had apparent CSS benefit compared with any other age group (all, P < 0.01). Interestingly, for the patients with no surgery, radiation and no radiation subgroup, the age < 50 had no apparent CSS benefit only compared with age 50–59 (all, P > 0.05). In conclusion, our study demonstrated that the SCLC patients with aged < 50 tended had a better survival benefit, especially for patients with AJCC stage III.